DNA Sequencing Market Size, Share & Analysis Report, 2023-2032
The global DNA sequencing market size was exhibited at USD 12.72 billion in 2022 and is projected to hit around USD 64.37 billion by 2032, growing at a CAGR of 17.6% during the forecast period 2023 to 2032.
Key Pointers:
DNA Sequencing Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 14.96 Billion |
| Market Size by 2032 | USD 64.37 Billion |
| Growth Rate From 2023 to 2032 | CAGR of 17.6% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | Product and Services, Technology, workflow, Application, End-use |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key Companies Profiled | Agilent Technologies, Inc.; Thermo Fisher Scientific, Inc.; Illumina, Inc.; Pacific Biosciences of California, Inc, QIAGEN; F. Hoffmann-La Roche Ltd.; Oxford Nanopore Technologies Ltd.; Macrogen, Inc.; Perkin Elmer, Inc.; BGI; Bio-Rad Laboratories, Inc.; Myriad Genetics; PierianDx; Eurofins Scientific; Intrexon Bioinformatics Germany GmbH |
Rapid advancements in sequencing technology and bioinformatics have enabled the identification of DNA variations. These advancements also determine variants associated with increased risk for disease. With a widespread application of Next-generation Sequencing (NGS) and Whole-genome Sequencing (WGS), a large range of genes can be tested in a single diagnostic platform at the same time, which expands the utility of DNA sequencing in clinical diagnosis applications. Personalized targeted sequencing of tumor accelerates the identification of mutations and further identifies cancer target or pathway for which pharmacological treatments are developed. The emergence of global-scale projects incorporating NGS protocols generates new foundational knowledge about oncology precision medicine.
ransform Oncology Care, a precision medicine program launched by CVS Health in December 2019, leverages genomics technology to plan personalized cancer treatment plans. An exponential rise in the COVID-19 cases has driven the demand for these technologies in large-scale, rapid genomic sequencing projects to monitor the viral spread and guide treatments in the future. The National Health Service of U.K., Genomics England, and Genetics of Mortality in Critical Care partnered with Illumina to generate whole-genome sequences of 35,000 COVID-19 affected U.K. citizens in May 2020. This propels the demand for DNA sequencing in COVID-19 diagnosis.
DNA sequencing has brought a paradigm shift in the proteomic and genomic research as it is highly accurate and high-throughput technology that is used for a variety of applications, such as de novo assembly, WGS, and DNA resequencing. Thereby, this technology is readily adopted in several academic research institutes for research studies. Illumina installed NovaSeq 6000 Sequencing System at the Whitehead Institute for Biomedical Research, Massachusetts, the U.S., in June 2020.
Efforts undertaken by the Centers for Medicare and Medicaid Services (CMS), Association for Molecular Pathology, as well as commercial payers, such as Blue Cross Blue Shield and Aetna, to boost the clinical usage of sequencing technologies, drives the market for DNA sequencing. For instance, in January 2020, CMS expanded the coverage of NGS-based diagnostic tests for ovarian and breast cancer patients, therefore providing more opportunities for patients to personalize their cancer care.
Some of the prominent players in the DNA Sequencing Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global DNA Sequencing market.
By Product & Services
By Technology
By Workflow
By Application
By End-use
By Region
Chapter 1 DNA Sequencing Market: Methodology and Scope
1.1 Research Assumptions
1.2 Research Methodology
1.3 Information Procurement
1.4 Information or Data Analysis
1.5 Market Formulation & Validation
1.6 Market Modelling
1.7 Global Market: CAGR Calculation
1.8 Objectives
1.8.1 Objective 1
1.8.2 Objective 2
Chapter 2 DNA Sequencing Market: Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.3 Competitive Insights
2.4 Market Summary
Chapter 3 DNA Sequencing Market: Market Variables, Trends, And Scope
3.1 Market Trends and Outlook
3.2 Market Lineage Outlook
3.2.1 Parent market outlook
3.2.2 Related/ancillary market outlook
3.3 Technology Overview
3.3.1 Technology timeline
3.4 Penetration & Growth Prospect Mapping for Applications, 2019
3.5 Impact of COVID-19
3.5.1 Utility of genome sequencing to track the spread of COVID-19
3.6 Market Dynamics
3.6.1 Market driver analysis
3.6.1.1 Rise in incidence of genetic disorders and cancer
3.6.1.2 Declining cost of genetic sequencing
3.6.1.3 Technological advancements in sequencing techniques and data integration
3.6.1.4 Increase in the penetration rate of companion diagnostics and personalized medicine
3.6.2 Market restraint analysis
3.6.2.1 Limitations associated with DNA sequencing
3.6.2.2 Ethical & legal limitations of DNA sequencing
3.6.3 Market challenge analysis
3.6.3.1 Production and bioinformatics challenges associated with sequencing
3.6.4 Market opportunities analysis
3.6.4.1 Funding and investments in the field of DNA sequencing
3.6.4.2 Advent of single-cell sequencing
3.7 Business Environment Analysis
3.7.1 SWOT analysis; by factor (political & legal, economic and technological)
3.7.2 Porter’s Five Forces Analysis
Chapter 4 DNA Sequencing Market: Competitive Analysis
4.1 Recent Developments & Impact Analysis, by Key Market Participants
4.2 Company/Competition Categorization
4.3 Vendor Landscape
4.3.1 Top vendors for sequencing reagents
4.3.2 List of key service providers
4.3.3 List of vendors for sequencing data analysis
4.4 Public Companies
4.4.1 Company financial size
4.4.2 Product portfolio
4.4.3 Geographic footprint
4.4.4 Strategic initiatives
4.5 Private Companies
4.6 Major Deals & Strategic Alliances Analysis
4.6.1 Partnerships & collaborations
4.6.2 Agreement
4.6.3 Merger & acquisition
4.7 Market Entry Strategies
Chapter 5 DNA Sequencing Market: Product & Services Business Analysis
5.1 DNA Sequencing Market: Product & Services Movement Analysis
5.2 Consumables
5.2.1 Global DNA sequencing consumables market, 2020 - 2032
5.3 Instruments
5.3.1 Global DNA sequencing instruments market, 2020 - 2032
5.4 Services
5.4.1 Global DNA sequencing services market, 2020 - 2032
Chapter 6 DNA Sequencing Market: Technology Business Analysis
6.1 DNA Sequencing Market: Technology Movement Analysis
6.2 Sanger Sequencing
6.2.1 Global Sanger Sequencing market, 2020 - 2032
6.3 Next-Generation Sequencing
6.3.1 Global next-generation sequencing market, 2020 - 2032
6.3.2 Whole genome sequencing
6.3.2.1 Global whole genome sequencing market, 2020 - 2032
6.3.3 Whole exome sequencing
6.3.3.1 Global whole genome sequencing market, 2020 - 2032
6.3.4 Targeted sequencing & resequencing
6.3.4.1 Global targeted sequencing & resequencing market, 2020 - 2032
6.4 Third-Generation Sequencing
6.4.1 Global third-generation sequencing market, 2020 - 2032
6.4.2 Single-molecule real-time sequencing (SMRT)
6.4.2.1 Global single-molecule real-time sequencing (SMRT) market, 2020 - 2032
6.4.3 Nanopore sequencing
6.4.3.1 Global nanopore sequencing market, 2020 - 2032
Chapter 7 DNA Sequencing Market: Workflow Business Analysis
7.1 DNA Sequencing Market: Workflow Movement Analysis
7.2 Pre-sequencing
7.2.1 Global DNA pre-sequencing market, 2020 - 2032
7.3 Sequencing
7.3.1 Global DNA-sequencing market, 2020 - 2032
7.4 Data Analysis
7.4.1 Global DNA-sequencing data analysis market, 2020 - 2032
Chapter 8 DNA Sequencing Market: Application Business Analysis
8.1 DNA Sequencing Market: Application Movement Analysis
8.2 Oncology
8.2.1 MGlobal DNA sequencing market for oncology, 2020 - 2032
8.3 Reproductive Health
8.3.1 Market for reproductive health, 2020 - 2032
8.4 Clinical Investigation
8.4.1 Market for clinical investigation, 2020 - 2032
8.5 Agrigenomics & Forensics
8.5.1 Market for agrigenomics & forensics, 2020 - 2032
8.6 HLA Typing/Immune System Monitoring
8.6.1 Market for HLA typing/immune system monitoring, 2020 - 2032
8.7 Metagenomics, Epidemiology & Drug Development
8.7.1 Market for metagenomics, epidemiology & drug development, 2020 - 2032
8.8 Consumer Genomics
8.8.1 Market for consumer genomics, 2020 - 2032
8.9 Other Applications
8.9.1 Market for other applications, 2020 - 2032
Chapter 9 DNA Sequencing Market: End-Use Business Analysis
9.1 DNA Sequencing Market: End-use Movement Analysis
9.2 Academic Research
9.2.1 Market for academic research, 2020 - 2032
9.3 Clinical Research
9.3.1 Market for clinical research, 2020 - 2032
9.4 Hospitals & Clinics
9.4.1 Market for hospitals & clinics, 2020 - 2032
9.5 Pharmaceutical & Biotechnology Companies
9.5.1 Market for pharmaceutical & biotechnology companies, 2020 - 2032
9.6 Other Users
9.6.1 Market for other users, 2020 - 2032
Chapter 10 DNA Sequencing Market: Region Business Analysis
10.1 DNA Sequencing Market: Regional Movement Analysis, 2019 & 2032
10.2 North America
10.2.1 Market estimates and forecast, 2020 - 2032
10.2.2 U.S.
10.2.2.1 Market estimates and forecast, by product & services, 2020 - 2032
10.2.2.2 Market estimates and forecast, by technology, 2020 - 2032
10.2.2.3 Market estimates and forecast, by workflow, 2020 - 2032
10.2.2.4 Market estimates and forecast, by application, 2020 - 2032
10.2.2.5 Market estimates and forecast, by end-use, 2020 - 2032
10.2.3 Canada
10.2.3.1 Market estimates and forecast, by product & services, 2020 - 2032
10.2.3.2 Market estimates and forecast, by technology, 2020 - 2032
10.2.3.3 Market estimates and forecast, by workflow, 2020 - 2032
10.2.3.4 Market estimates and forecast, by application, 2020 - 2032
10.2.3.5 Market estimates and forecast, by end-use, 2020 - 2032
10.3 Europe
10.3.1 Market estimates and forecast, 2020 - 2032
10.3.2 Germany
10.3.2.1 Market estimates and forecast, by product & services, 2020 - 2032
10.3.2.2 Market estimates and forecast, by technology, 2020 - 2032
10.3.2.3 Market estimates and forecast, by workflow, 2020 - 2032
10.3.2.4 Market estimates and forecast, by application, 2020 - 2032
10.3.2.5 Market estimates and forecast, by end-use, 2020 - 2032
10.3.3 U.K.
10.3.3.1 Market estimates and forecast, by product & services, 2020 - 2032
10.3.3.2 Market estimates and forecast, by technology, 2020 - 2032
10.3.3.3 Market estimates and forecast, by workflow, 2020 - 2032
10.3.3.4 Market estimates and forecast, by application, 2020 - 2032
10.3.3.5 Market estimates and forecast, by end-use, 2020 - 2032
10.3.4 France
10.3.4.1 Market estimates and forecast, by product & services, 2020 - 2032
10.3.4.2 Market estimates and forecast, by technology, 2020 - 2032
10.3.4.3 Market estimates and forecast, by workflow, 2020 - 2032
10.3.4.4 Market estimates and forecast, by application, 2020 - 2032
10.3.4.5 Market estimates and forecast, by end-use, 2020 - 2032
10.3.5 Italy
10.3.5.1 Market estimates and forecast, by product & services, 2020 - 2032
10.3.5.2 Market estimates and forecast, by technology, 2020 - 2032
10.3.5.3 Market estimates and forecast, by workflow, 2020 - 2032
10.3.5.4 Market estimates and forecast, by application, 2020 - 2032
10.3.5.5 Market estimates and forecast, by end-use, 2020 - 2032
10.3.6 Spain
10.3.6.1 Market estimates and forecast, by product & services, 2020 - 2032
10.3.6.2 Market estimates and forecast, by technology, 2020 - 2032
10.3.6.3 Market estimates and forecast, by workflow, 2020 - 2032
10.3.6.4 Market estimates and forecast, by application, 2020 - 2032
10.3.6.5 Market estimates and forecast, by end-use, 2020 - 2032
10.4 Asia Pacific
10.4.1 Market estimates and forecast, 2020 - 2032
10.4.2 Japan
10.4.2.1 Market estimates and forecast, by product & services, 2020 - 2032
10.4.2.2 Market estimates and forecast, by technology, 2020 - 2032
10.4.2.3 Market estimates and forecast, by workflow, 2020 - 2032
10.4.2.4 Market estimates and forecast, by application, 2020 - 2032
10.4.2.5 Market estimates and forecast, by end-use, 2020 - 2032
10.4.3 China
10.4.3.1 Market estimates and forecast, by product & services, 2020 - 2032
10.4.3.2 Market estimates and forecast, by technology, 2020 - 2032
10.4.3.3 Market estimates and forecast, by workflow, 2020 - 2032
10.4.3.4 Market estimates and forecast, by application, 2020 - 2032
10.4.3.5 Market estimates and forecast, by end-use, 2020 - 2032
10.4.4 India
10.4.4.1 Market estimates and forecast, by product & services, 2020 - 2032
10.4.4.2 Market estimates and forecast, by technology, 2020 - 2032
10.4.4.3 Market estimates and forecast, by workflow, 2020 - 2032
10.4.4.4 Market estimates and forecast, by application, 2020 - 2032
10.4.4.5 Market estimates and forecast, by end-use, 2020 - 2032
10.5 Latin America
10.5.1 Market estimates and forecast, 2020 - 2032
10.5.2 Brazil
10.5.2.1 Market estimates and forecast, by product & services, 2020 - 2032
10.5.2.2 Market estimates and forecast, by technology, 2020 - 2032
10.5.2.3 Market estimates and forecast, by workflow, 2020 - 2032
10.5.2.4 Market estimates and forecast, by application, 2020 - 2032
10.5.2.5 Market estimates and forecast, by end-use, 2020 - 2032
10.5.3 Mexico
10.5.3.1 Market estimates and forecast, by product & services, 2020 - 2032
10.5.3.2 Market estimates and forecast, by technology, 2020 - 2032
10.5.3.3 Market estimates and forecast, by workflow, 2020 - 2032
10.5.3.4 Market estimates and forecast, by application, 2020 - 2032
10.5.3.5 Market estimates and forecast, by end-use, 2020 - 2032
10.6 Middle East and Africa (MEA)
10.6.1 Market estimates and forecast, 2020 - 2032
10.6.2 South Africa
10.6.2.1 Market estimates and forecast, by product & services, 2020 - 2032
10.6.2.2 Market estimates and forecast, by technology, 2020 - 2032
10.6.2.3 Market estimates and forecast, by workflow, 2020 - 2032
10.6.2.4 Market estimates and forecast, by application, 2020 - 2032
10.6.2.5 Market estimates and forecast, by end-use, 2020 - 2032
10.6.3 Saudi Arabia
10.6.3.1 Market estimates and forecast, by product & services, 2020 - 2032
10.6.3.2 Market estimates and forecast, by technology, 2020 - 2032
10.6.3.3 Market estimates and forecast, by workflow, 2020 - 2032
10.6.3.4 Market estimates and forecast, by application, 2020 - 2032
10.6.3.5 Market estimates and forecast, by end-use, 2020 - 2032
Chapter 11 DNA Sequencing Market: Company Profile
11.1 Strategy Framework
11.2 Market Participation Categorization
11.3 Company Profiles
11.3.1 Agilent Technologies
11.3.1.1 Company overview
11.3.1.2 Financial performance
11.3.1.3 Product benchmarking
11.3.1.4 Strategic initiatives
11.3.2 Thermo Fisher Scientific, Inc.
11.3.2.1 Company overview
11.3.2.2 Life Technologies
11.3.2.2.1Company overview
11.3.2.3 Financial performance
11.3.2.4 Product benchmarking
11.3.2.5 Strategic initiatives
11.3.3 Illumina, Inc.
11.3.3.1 Company overview
11.3.3.2 Financial performance
11.3.3.3 Product benchmarking
11.3.3.4 Strategic initiatives
11.3.4 QIAGEN
11.3.4.1 Company overview
11.3.4.2 Ingenuity
11.3.4.2.1Company overview
11.3.4.3 CLC Bio
11.3.4.3.1Company overview
11.3.4.4 Financial performance
11.3.4.5 Product benchmarking
11.3.4.6 Strategic initiatives
11.3.5 F. Hoffmann-La Roche Ltd.
11.3.5.1 Company overview
11.3.5.2 Financial performance
11.3.5.3 Product benchmarking
11.3.5.4 Strategic initiatives
11.3.6 Oxford Nanopore Technologies
11.3.6.1 Company overview
11.3.6.2 Financial performance
11.3.6.3 Product benchmarking
11.3.6.4 Strategic initiatives
11.3.7 Macrogen, Inc.
11.3.7.1 Company overview
11.3.7.2 Financial performance
11.3.7.3 Product benchmarking
11.3.7.4 Strategic initiatives
11.3.8 Perkin Elmer, Inc.
11.3.8.1 Company overview
11.3.8.2 PerkinElmer Genomics
11.3.8.2.1 Company overview
11.3.8.3 Financial performance
11.3.8.4 Product benchmarking
11.3.8.5 Strategic initiatives
11.3.9 Pacific Biosciences Of California, Inc.
11.3.9.1 Company overview
11.3.9.2 Financial performance
11.3.9.3 Product benchmarking
11.3.9.4 Strategic initiatives
11.3.10 BGI
11.3.10.1 Company overview
11.3.10.2 Complete Genomics Incorporated
11.3.10.2.1 Company overview
11.3.10.3 Financial performance
11.3.10.4 Product benchmarking
11.3.10.5 Strategic initiatives
11.3.11 Bio-Rad Laboratories, Inc.
11.3.11.1 Company overview
11.3.11.2 GnuBio
11.3.11.2.1 Company overview
11.3.11.3 Financial performance
11.3.11.4 Product benchmarking
11.3.11.5 Strategic initiatives
11.3.12 Myriad Genetics, Inc.
11.3.12.1 Company overview
11.3.12.2 Financial performance
11.3.12.3 Product benchmarking
11.3.12.4 Strategic initiatives
11.3.13 PierianDx
11.3.13.1 Company overview
11.3.13.2 Tute Genomics
11.3.13.2.1 Company overview
11.3.13.2.2 Knome, Inc.
11.3.13.2.2.1 Company overview
11.3.13.3 Financial performance
11.3.13.4 Product benchmarking
11.3.13.5 Strategic initiatives
11.3.14 Intrexon Bioinformatics Germany GmbH
11.3.14.1 Company overview
11.3.14.2 Financial performance
11.3.14.3 Product benchmarking
11.3.14.4 Strategic initiatives
11.3.15 Eurofins Scientific
11.3.15.1 Company overview
11.3.15.2 GATC Biotech GmbH
11.3.15.2.1 Company overview
11.3.15.3 Financial performance
11.3.15.4 Product benchmarking
11.3.15.5 Strategic initiatives
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers